Genscript Biotech (GNNSF) Stock Price, News & Analysis

Company Overview

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation. The Biologics Development Services segment offers end-to-end service offerings to biologics development and manufacturing for biopharma and biotech partners, as well as therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor CAR-T cell therapies for the treatment of liquid and solid tumors. It has a strategic partnership with Multiply Labs for automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

Key Stats

• Today's Range: C$1.67 to C$1.67
• 50-Day Range: C$1.30 to C$2.20
• 52-Week Range: C$1.12 to C$2.20
• Volume: 200 shs
• Average Volume: 3,358 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNNSF Stock Analysis - Frequently Asked Questions

How have GNNSF shares performed this year?

Genscript Biotech's stock was trading at C$1.27 at the beginning of the year. Since then, GNNSF shares have increased by 31.5% and is now trading at C$1.67.

How do I buy shares of Genscript Biotech?

Shares of GNNSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:GNNSF
• CIK: N/A
• Web: www.genscript.com
• Phone: 862558897288
• Fax: N/A
• Employees: 6,937
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A